Navigation Links
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Date:10/7/2008

allel-group, four-week study with dose escalations in 414 adults aged 18 to 55 years, adults with ADHD experienced significant improvements in ADHD symptoms within one week of treatment with once-daily VYVANSE.

Treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo, with a mean reduction in ADHD Rating Scale (ADHD-RS-IV) scores (16.2 to 18.6 points; P<.0001); demonstrating a 40 to 45 percent decrease at endpoint. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing response to treatment. The scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision(R), a publication of the American Psychiatric Association.

Investigators also measured the efficacy of VYVANSE using the Clinical Global Impressions-Improvement (CGI-I) scale. On this scale, the percentage of adults taking VYVANSE rated by investigators as "much improved" or "very much improved" ranged from 57 to 61 percent at endpoint and was significantly greater than placebo (P<.01). The CGI-I is a standard assessment used to rate a patient's improvement over time.

The most common adverse events in the study were decreased appetite, difficulty falling asleep, and dry mouth.

"This study was one of the largest controlled stimulant trials in adults with ADHD, and these data reinforce the importance of VYVANSE as a new once-daily treatment option for adults with ADHD that significantly improved their ADHD symptoms," said Mike Cola, President of Shire's Specialty Pharmaceuticals business. "Shire recognizes the need for more research on ADHD in the adult population and is committed to advancing the science of ADHD and providing treatments that help children and adults diagnosed with ADHD to lead more productive lives."

VYVANSE is a therapeutically inactive prodrug, in which d-
'/>"/>

SOURCE Shire Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... TAMPA, Fla. , Sept. 17, 2014   ... announced today that Business Insurance magazine has ... Insurance" distinction for the third year in a row. ... joint effort of Business Insurance  and the Best ... evaluation, is open to all publicly or privately-held insurance ...
(Date:9/17/2014)... ANGELES and LEIPZIG, Germany ... today announced that it has entered into an ... the development of antibody-based imaging agents to image ... "Our collaboration with Novotectid expands ImaginAb,s capability to precisely ... immune-oncology and autoimmune disease areas. The ability to ...
(Date:9/17/2014)... PALO ALTO, Calif. , Sept. 17, 2014 /PRNewswire/ ... of the Company,s Phase 2 clinical program of NP001 ... Lou Gehrig,s disease) are being highlighted today ... of the ALS Research Group , being held in ... According to a  post hoc  analysis, administration of a ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Reportlinker.com announces that a new market research report ... Drug Delivery in Central Nervous System Diseases - ... The delivery of drugs ... in the treatment of neurological disorders. Drugs may ...
... Robbins & Myers, Inc. (NYSE: ... its Romaco businesses to a group of funds led ... investment firm.  Total consideration was approximately euro 65 million ... and euro 4 million of assumed liabilities and is ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
(Date:9/17/2014)... (PRWEB) September 17, 2014 As kinship ... for children who cannot live with their parents, emphasis ... to continue to enhance services and supports for kinship ... America’s (CWLA) National Kinship Care Conference is being held ... knowledge of best practice, policy, program and service development ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... July 1 AlphaMed Press, co-publisher of the journal ... stem cells and regenerative medicine, has promoted Miodrag Stojkovic ... is Deputy Director of the Prince Felipe Research Centre ... Spain. He led the team that first announced derivation ...
... ... two winners of their 2009 North American Grant Program. Exiqon had recently announced ... non-profit institutions across North America, engaged in microRNA research. , ... (PRWEB) July 1, 2009 -- Exiqon A/S ...
... ... the past 30 years, The Free Choice Foundation is a newly established grassroots organization ... with regards to healthcare. , ... Tokyo, Japan (PRWEB) July 1, 2009 -- Based on the spirit of ...
... Also recommends dosing limits for OTC products that contain ... liver damage. , TUESDAY, June 30 (HealthDay News) ... combine acetaminophen with an opiate narcotic, should be banned, ... like Tylenol or Excedrin, should be lowered, a U.S. ...
... Disease , , WASHINGTON, June 30 Today Lung ... Cancer illustrating again the devastating toll caused by lung cancer. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) ... analyzes the most recent available data from the National Institutes of ...
... Andrew Ordon, co-host of the syndicated talk show The ... a non-invasive skin contouring procedure, at his state-of-the-art surgical facilities ... is the perfect option for someone who wants to look ... explains Ordon. "There is little to no downtime with this ...
Cached Medicine News:Health News:STEM CELLS Promotes Miodrag Stojkovic to Editor 2Health News:Exiqon Announces 2009 North American Grant Award Winners 2Health News:Exiqon Announces 2009 North American Grant Award Winners 3Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 2Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 2Health News:FDA Panel Urges Ban on Vicodin, Percocet 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 4Health News:Lung Cancer Alliance Releases Updated 2009 Facts About Lung Cancer 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
50L...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Medicine Products: